{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:38:10Z","timestamp":1761946690478,"version":"3.44.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.jinf.2004.03.009","type":"journal-article","created":{"date-parts":[[2004,5,13]],"date-time":"2004-05-13T07:04:21Z","timestamp":1084431861000},"page":"115-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections"],"prefix":"10.1016","volume":"49","author":[{"given":"Donald E","family":"Low","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Felmingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve D","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manickam","family":"Rangaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roomi","family":"Nusrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2004.03.009_BIB1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1001\/archinte.159.21.2531","article-title":"Outpatient visits for infectious diseases in the United States, 1980 through 1996","volume":"159","author":"Armstrong","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jinf.2004.03.009_BIB2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2004.03.009_BIB3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0196-0644(98)70350-6","article-title":"Patients hospitalized after initial outpatient treatment for community-acquired pneumonia","volume":"31","author":"Minogue","year":"1998","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jinf.2004.03.009_BIB4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"Niederman","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.jinf.2004.03.009_BIB5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0149-2918(00)88310-1","article-title":"Treatment cost of acute exacerbations of chronic bronchitis","volume":"21","author":"Niederman","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.jinf.2004.03.009_BIB6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1524-4733.2001.45049.x","article-title":"The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales","volume":"4","author":"McGuire","year":"2001","journal-title":"Value Health"},{"key":"10.1016\/j.jinf.2004.03.009_BIB7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2004.03.009_BIB8","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.113.3_Supplement.199S","article-title":"Acute exacerbations of bronchitis. An international comparison","volume":"113","author":"Ball","year":"1998","journal-title":"Chest"},{"issue":"Suppl. 6","key":"10.1016\/j.jinf.2004.03.009_BIB9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1067\/mhn.2002.130030","article-title":"Issues in the management of bacterial sinusitis","volume":"127","author":"Bishai","year":"2002","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"Suppl 9A","key":"10.1016\/j.jinf.2004.03.009_BIB10","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/S0002-9343(01)01025-7","article-title":"Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment","volume":"111","author":"Pfaller","year":"2001","journal-title":"Am J Med"},{"issue":"Suppl. 9A","key":"10.1016\/j.jinf.2004.03.009_BIB11","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1016\/S0002-9343(01)01027-0","article-title":"Epidemiology of sinusitis in the primary care setting: results from the 1999\u20132000 respiratory surveillance program","volume":"111","author":"Sokol","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.jinf.2004.03.009_BIB12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005792-199009000-00004","article-title":"New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases","volume":"69","author":"Fang","year":"1990","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jinf.2004.03.009_BIB13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0891-5520(05)70207-5","article-title":"Community-acquired pneumonia: epidemiology, etiology, treatment","volume":"12","author":"Marrie","year":"1998","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.jinf.2004.03.009_BIB14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00019048-199906000-00003","article-title":"Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment","volume":"8","author":"Hammerschlag","year":"1999","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jinf.2004.03.009_BIB15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/jama.286.10.1181","article-title":"Antibiotic treatment of adults with sore throat by community primary care physicians. A national survey, 1989\u20131999","volume":"286","author":"Linder","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2004.03.009_BIB16","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2004.03.009_BIB17","first-page":"2","article-title":"Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis","volume":"182","author":"Brooks","year":"2000","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jinf.2004.03.009_BIB18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1183\/09031936.98.11040986","article-title":"Guidelines for management of adult community-acquired lower respiratory tract infections","volume":"11","year":"1998","journal-title":"Eur Respir J"},{"issue":"Suppl. 2","key":"10.1016\/j.jinf.2004.03.009_BIB19","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/320181","article-title":"Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Hoban","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2004.03.009_BIB20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0732-8893(02)00522-9","article-title":"Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999\u20132000: findings of the PROTEKT surveillance study","volume":"45","author":"Hoban","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl. A","key":"10.1016\/j.jinf.2004.03.009_BIB21","first-page":"3","article-title":"Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study","volume":"44","author":"Felmingham","year":"2002","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2004.03.009_BIB22","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1128\/AAC.47.7.2370-2372.2003","article-title":"Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001","volume":"47","author":"Katz","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB23","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.42.8.2138","article-title":"In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB24","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.42.11.3032","article-title":"Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay","volume":"42","author":"Pankuch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB25","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/AAC.42.6.1515","article-title":"In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae","volume":"42","author":"Roblin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB26","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Sch\u00fclin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/47.6.837","article-title":"Lung concentrations of telithromycin after oral dosing","volume":"47","author":"Khair","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB29","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.45.11.3104-3108.2001","article-title":"Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647)","volume":"45","author":"Muller-Serieys","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2004.03.009_BIB31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Dunbar","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jinf.2004.03.009_BIB32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jinf.2004.03.009_BIB33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1469-0691.2003.00678.x","article-title":"Efficacy of telithromycin, a new once-daily ketolide antimicrobial, in the treatment of community-acquired pneumonia","volume":"9","author":"Carbon","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2004.03.009_BIB34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/030079902125001191","article-title":"Efficacy and safety of telithromycin in community-acquired pneumonia","volume":"18","author":"van Rensburg","year":"2002","journal-title":"Curr Opin Med Res"},{"year":"2001","series-title":"Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae","author":"Fogarty","key":"10.1016\/j.jinf.2004.03.009_BIB35"},{"year":"2004","series-title":"Efficacy of a 7-day course of oral telithromycin 800 mg once daily in community-acquired pneumonia caused by resistant Streptococcus pneumoniae","author":"Fogarty","key":"10.1016\/j.jinf.2004.03.009_BIB36"},{"year":"2002","series-title":"Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs. clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia","author":"Tellier","key":"10.1016\/j.jinf.2004.03.009_BIB37"},{"key":"10.1016\/j.jinf.2004.03.009_BIB38","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/rmed.2002.1382","article-title":"Telithromycin is as effective as amoxicillin\/clavulanate in acute exacerbations of chronic bronchitis","volume":"96","author":"Aubier","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.jinf.2004.03.009_BIB39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/147323000303100301","article-title":"Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis","volume":"31","author":"Zervos","year":"2003","journal-title":"J Int Med Res"},{"year":"2003","series-title":"Five-day telithromycin is as effective as 10 day clarithromycin in the treatment of acute exacerbations of chronic bronchitis","author":"Fogarty","key":"10.1016\/j.jinf.2004.03.009_BIB40"},{"key":"10.1016\/j.jinf.2004.03.009_BIB41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jinf.2004.03.009_BIB42","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/014556130308200812","article-title":"Efficacy and tolerability of the ketolide telithromycin (HMR 3647) for 5 or 10 days vs. amoxicillin\/clavulanic acid for 10 days in the treatment of acute maxillary sinusitis (AMS) in adults","volume":"82","author":"Luterman","year":"2003","journal-title":"Ear Nose Throat"},{"key":"10.1016\/j.jinf.2004.03.009_BIB43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/194589240301700610","article-title":"Telithromycin vs. cefuroxime axetil in acute maxillary sinusitis","volume":"17","author":"Buchanan","year":"2003","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.jinf.2004.03.009_BIB44","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS). Document M100S11. Wayne, PA: NCCLS; 2001."},{"key":"10.1016\/j.jinf.2004.03.009_BIB45","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1128\/AAC.40.11.2562","article-title":"Detection of erythromycin-resistant determinants by PCR","volume":"40","author":"Sutcliffe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. S1","key":"10.1016\/j.jinf.2004.03.009_BIB46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/dkf806","article-title":"Molecular characterization of macrolide mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT study 1999\u20132000","volume":"50","author":"Farrell","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB47","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/dkg153","article-title":"Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin","volume":"51","author":"Fogarty","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB48","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/AAC.45.6.1688-1692.2001","article-title":"In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models","volume":"45","author":"Bonnefoy","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"year":"2001","series-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP)","author":"Drusano","key":"10.1016\/j.jinf.2004.03.009_BIB49"},{"key":"10.1016\/j.jinf.2004.03.009_BIB50","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2004.03.009_BIB51","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1086\/516366","article-title":"Once daily sparfloxacin versus high dose amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults","volume":"26","author":"Aubier","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2004.03.009_BIB52","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0149-2918(96)80067-1","article-title":"Clinical efficacy of dirithromycin in patients with bacteremic pneumonia","volume":"18","author":"Hernandez","year":"1996","journal-title":"Clin Ther"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445304000623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445304000623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:26:47Z","timestamp":1758986807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445304000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0163445304000623"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2004.03.009","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2004.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}